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Sciatic nerveNeuropathic pain refers to pain that originates from pathology of the nervous system. Diabetes, infection
(herpes zoster), nerve compression, nerve trauma, and autoimmune diseases are examples of diseases that
may cause neuropathic pain. Unfortunately no satisfactory treatment is yet available for this type of pain.
This consideration has led to an explosion of interest for the underlying mechanisms, accompanied by a
growing number of animal models. In recent years, most of the neuropathic pain models initially developed
in the rat have been translated to mice in order to exploit the resource represented by genetically modiﬁed
mice. Obviously the most useful animal models of pain would be ones in which the etiology of the pain
would be endogenous and not induced by the experimenters: together with the classic models based on
peripheral nerve ligation, in the last years other techniques are being developed that mimic more closely
clinical pain syndromes, often by attempting to induce the disease associated to neuropathic pain. Although
several variables must be taken into account when using animal models for mimicking clinical neuropathic
pain, the huge number of models that are now reproducible and well characterized should help to reach
important goals in the comprehension of mechanisms and to discover novel therapeutic target for this
disease.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
A deﬁnition of neuropathic pain useful for both clinical and research
purposes is that recently developed by Treede et al. [1]: “pain arising as a
direct consequence of a lesion or disease affecting the somatosensory
system”. Neuropathic pain canbedivided intoperipheral or central based
on the anatomic location of the lesion or the disease: peripheral nervous
system(PNS, e.g. peripheral nerves, dorsal root ganglia (DRG), and dorsal
roots) and central nervous system (CNS e.g. spinal cord and thalamus).
These injuries arise from diabetic neuropathy, viral infections (Herpes
virus, HIV), major surgeries or trauma (amputation, thoracotomy,
entrapment or compression), spinal cord injury, and stroke. Examples
of neuropathic pain include carpal tunnel syndrome, trigeminal
neuralgia, post herpetic neuralgia, radiculopathy, phantom limb pain,
complex regional pain syndromes and the various peripheral neurop-
athies, such as those deriving from chemotherapy. Sensory loss and
spontaneous pain together with a sensory gain, such as mechanical
allodynia (pain resulting from stimuli that are normally innocuous) are
distinct symptoms of neuropathic pain, although this pain is also
characterized by heat and mechanical hyperalgesia (increased pain
responses to thermal and mechanical stimuli), all of which affect
adversely the quality of patients' daily life [1,2]. Neuropathic pain is a
common clinical problem affecting millions people in the USA and39 2 50316933.
ote).
ll rights reserved.Europe, and it has become a major problem since unfortunately it
tends to be long-lasting (neuropathic pain often lasts years or even
indeﬁnitely) and difﬁcult to manage due to the poor efﬁcacies and
severe well-known adverse side effects associated with the current
conventional antinociceptive treatments [3]. The search for new drug
molecules to alleviate this intractable pain is priority nowadays, and
elucidating the molecular mechanisms of neuropathic pain is an
important prerequisite for the rational development of novel
analgesic drugs for the therapy of this chronic pain.
Neuropathic pain arises from both PNS and CNS causes and many
etiologists have been recognized in the human: a partial list is given in
Table 1 [4]. Unfortunately the existence of different pathological
conditions leading to the development of neuropathic pain makes
more difﬁcult the identiﬁcation of a simple and reliable animal model
and explains the huge numbers of models present in the literature.
2. Murine models of neuropathic pain
Animal research must always be evaluated by three general
criteria: the generation of knowledge, the ability of the study to be
reproduced, the relevance of the study and the predictive validity of
clinical pain states. Despite the controversy on whether data from
animal models can be applied to humans, this research serves as a
valuable source of information in many medical areas. Animal models
provide pivotal systems for preclinical studies of neuropathic pain
and serve as an experimental basis for mechanistic investigations
and testing new therapeutic interventions. Experiments featuring
Table 1
Partial list of ethiologies of neuropathic pain in the human.
Mechanical nerve injuries/compression
Spinal cord injuries
Metabolic diseases (e.g., diabetes)
Viral diseases (e.g., herpes zoster, HIV)
Inﬂammatory/immunological mechanism (e.g., multiple sclerosis)
Alcoholism (vitamin B12 deﬁciency)
Iatrogenic: chemotherapy of cancer, AIDS or tuberculosis (e.g., cis-platinum)
Vascular lesions of the hypothalamus
Congenital (e.g., Charcot-Marie-Tooth)
Aging
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becoming more common over time in published papers. Non-human
animals cannot self-report, but their behaviours in response to noxious
stimuli can be reliably and objectively scored.
Most of animal models of neuropathic pain were generated
starting from the late 1980, using rat as preferred species. More
recently pain models originally developed in rats have been
transposed for use in mice; a strong motive for the use of mice is
the availability of genetically characterized or manipulated inbred
strains, particularly transgenic mouse lines in which speciﬁc proteins
or signal transduction component have been altered throughout
genetic knockout technology. Although transgenic technologies has
transformed basic pain research, allowing the role of individual
proteins in pain to be studied even in the absence of selective ligands
or antibodies, the complexity of the chronic pain phenomenon has
made it difﬁcult to asses the true value of these advances.
In addition, in pain studies more than in other animal models of
disease, particular care has to be given to the strains used, since a
strong inﬂuence of genetic background on pain sensitivity exists.
A common pitfall of all rodent models of neuropathic pain is the
inappropriateness of the outcomemeasures utilized. In fact they focus
on stimulus-evoked pain and hyperreﬂexia at a particular moment in
time, whereas a high proportion of patients with neuropathic pain
have ongoing, spontaneous pain and sensory loss. The recognition of
spontaneous pain in experimental animals is particularly difﬁcult.
Weight loss, sleep disturbances, reduced movement, spontaneous
paw lifting, scratching or shaking have all been accepted to reﬂect
spontaneous pain [2]. Awareness is leading to the use of more
complex measures of integrated pain behaviour including evaluation
of neuropathic pain comorbidities, such as the presence of affective
component of persistent pain [5], frequently observed in patients.
However while this more comprehensive paradigm to evaluate
neuropathic pain is increasingly applied to the rat model, this aspect
has not been yet taken into enough consideration in themore recently
developed murine models.
The numerousmodels of neuropathic pain inmice can be classiﬁed
in many different ways.
In the present review we divide them into ﬁve gross categories:
central pain models,
peripheral nerve injury models,
models of disease-induced neuropathic pain
iatrogenic (drug-induced) neuropathic pain, and
inherited neuropathies.
3. Central pain models
These models mimic neuropathic pain resulting from CNS
pathologies. Central pain syndromes represent a form of neuropathic
pain that is associated with lesions of the brain or the spinal cord after
a stroke or other traumatic injury. Stroke is the leading cause of
disability in the industrialized world and it is estimated that up to 8%
of stroke victims suffer from some form of central post-stroke pain.3.1. Thalamic syndrome
Thalamic syndrome is a form of central pain that typically results
from stroke in the thalamus and is characterized by spontaneous
pain, attacks of allodynia, and dysesthesia. The lack of suitable
thalamic syndrome models has hampered research into the
dysregulated perception of pain resulting from stroke in the
thalamus. Therefore, the development and characterization of a
rodent model of thalamic syndrome was the ﬁrst step to discover
the underlying mechanisms of this disease and possible therapeutics.
Very recently a rat model of this syndrome was developed based on
a small hemorrhagic stroke lesion induced by collagenase injection
in the ventral posterolateral nucleus of the rat thalamus [6]. Animals
displayed hyperesthesia in response to mechanical pinch stimula-
tion, with sensitivity localized in the hind limb and increased
thermal sensitivity. This novel model has not been developed in
mice yet.
3.2. Spinal cord injury (SCI)
SCI occurs in most countries at an annual rate of 20–40 persons per
millions. Following mechanical injury to the spinal cord, a wave of
secondary pathological changes occurs and ampliﬁes the extent of the
initial damage. Apoptosis is critical in triggering collateral damage
after primary injury in SCI. Spontaneous and evoked pain are
frequently sequelae of traumatic or ischemic SCI. Several models of
central pathologies causing neuropathic pain were raised mainly in
rats and mostly based on SCI caused by contusion or weight dropping,
spinal cord compression, excitatory neurotoxins, photochemically
induced ischemia, spinal cord hemisection, crushing of spinal cord. All
these models were adapted for mice [7,8]. As described above, the
development of reliable models of neurotrauma in mice provides
great promise for evaluating overexpression or inactivation of a gene
on lesion pathophysiology and functional outcome.
3.2.1. Contusive models
The spinal cord contusion is the oldest and most widely used
model and has been recently employed also in mice; in addition to
motor dysfunction, this injury elicits sensory dysfunction including
neuropathic pain, such as tactile allodynia and thermal hyperalgesia
[9-11]. Several techniques can be applied in order to mimic SCI. Some
examples are dorsal column crush surgery [7]; spinal cord completely
transected intervertebrally with microscissors inserted between the
9th and 10th thoracic vertebrae [12]; laminectomy at T9 or T5–T6 and
compression with a vascular clip (clip compression: simple, reliable
and inexpensive model) [13,14].
3.2.2. Excitotoxic models
Intraspinal or intrathecally injection of some excitoxins, such as
quisqualic acid or other excitatory aminoacids (glutamate, N-
methylaspartate, kainic acid) have been reported to produce long
lasting spontaneous pain, mechanical allodynia and thermal hyper-
algesia also in mice [15].
3.2.3. Photochemical model
Over the past two decades, the photochemical model of SCI,
developed by Watson et al. [16] has been one of the most reliable and
reproducible graded experimental models of SCI in rats [17] widely
used in neurotrauma research. This model consists in an intravenous
injection of the photosensitising dye, Rose Bengal, and an irradiation
of the translucent dorsal surface of the T9 vertebral laminawith a 560-
nm wavelength-light for 3–8 min (the beam of a xenon lamp,
conveyed by ﬁber optics). This irradiation induced excitation of the
injected dye in the spinal cord microvasculature. The resultant
photochemical reaction led to vascular stasis and ischemia. The
model is successfully used now also inmice where it was conﬁrmed to
Fig. 1. Schematic cartoon representing ﬁbers and sciatic nerve in the mouse limb. The
main injury types applied to the nerve are reported. SNL: spinal nerve ligation; PNI:
partial nerve injury; CCI: chronic constriction injury; SNI spared nerve injury.
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ischemic SCI [18].
4. Peripheral nerve injury models
The majority of neuropathic pain models use nerve injury to
induce hyperalgesia and allodynia in rodents, which are similar to the
symptoms of neuropathic pain in humans. Numerous models have
been developed in rodents that generate a mixture of intact and
injured ﬁbres within a peripheral nerve, usually the sciatic, for ease of
access and its relatively large size. Neuropathic pain behaviour is
thought to be attributable to altered properties in the intact rather
than the damaged ﬁbres.
Numerous types of nerve lesions have been employed including
transection, resection, crush, complete or partial tight ligation,
cryoneurolysis, and loose ligation with inﬂammatory materials.
These variations in nerve lesions may be categorized by criteria as
follows: the onset, acute or progressive; completeness, entire vs.
partial nerve involvement; duration, permanent or regenerative; the
injury's inﬂammatory potential, immune cells recruitment at the site
of injury either spontaneous or induced by exogenous stimulus
(chromic gut). The type of nerve lesion can clearly inﬂuence the
character of the ensuing neuropathic behaviours [19].
4.1. Complete lesion
4.1.1. Sciatic nerve (neuroma model)
Phantom limb pain occurs in about 80% of amputees [20], but its
intensity, frequency and duration varies widely, even for similar
lesions [21]. Following complete nerve transection of the sciatic nerve
of rats and mice, a neuroma develops at the proximal nerve stump,
consisting of regenerative nerve sprouting in all directions. This lesion
results in immediate and irreversible interruption of electrical nerve
conduction, followed byWallerian degeneration of the axons distal to
the lesion and sprouting of the proximal axonal stumps in an attempt
to regenerate the nerve ﬁber. Complete lesions (total nerve
transection and ligation) of the sciatic nerve simulating the clinical
conditions of amputation are not practical for behavioural studies
since they producemotor weakness and, until sufﬁcient regenerations
occurs (3–4 weeks), preclude most evoked response testing. In this
model self-attack and mutilation of the denervated leg were
observed; the label “autotomy” was given to this behaviour, a term
commonly used in studies where a form of excessive self-care or self-
grooming occurs that results in bite wounds and eventually in the
self-amputation of digits. Although autotomy is not a normal response
by humans to total limb denervation or chronic pain, it occours in
species ranging from rodents to primate. There have been some
controversies on whether or not autotomy behaviour is a sign of
spontaneous pain. Similar behaviours can be induced in animals by
skin irritations or skin diseases assumed to induce itching. It has been
argued that the absence of sensory feedback from the denervated leg
may result in the self attack because the animal does not recognize the
anesthetic limb as part of its body and therefore autotomy should be
considered a consequence of the presence of a numb insensate yet
painless limb [22,23]. However there are many reasons for believing
that autotomy in rodent reﬂects ongoing dysesthesia or pain rather
than simple dumbness. Autotomy responds to drugs known to be
effective in treatment of neuropathic pain including local anaes-
thetics, opiates, benzodiazepines, tricyclic antidepressants and sym-
patholytic agents [24], while drugs such as non-steroidal
antiinﬂammatory drugs that are minimally effective against neuro-
pathic pain in the clinic do not affect autotomy [25]. It has been clearly
shown that rendering a rodent limb numb by prolonged period with
local anesthetic block does not trigger autotomy [25]. Moreover this
response has been recently reported also in other models of
neuropathic pain such as the Chung model (see paragraph 4.2.3)[25]. Therefore it is widely assumed now that excessive grooming and
autotomy following a nerve lesion reﬂect chronic spontaneous
neuropathic pain [2,26-28]. Autotomy levels vary greatly among
different inbred, outbred and selected lines of mice and rats under
identical conditions [29-31] demonstrating that genetic factors play a
major role in autotomy in these rodents. Identifying a gene having a
major effect on autotomy may provide targets for the development of
novel analgesics for neuropathic pain in humans [24].
4.1.2. Brachial plexus avulsion in mice
It has been reported that in humans, the brachial plexus avulsion
(BPA) induces a constant crushing and intermittent shooting pain that
remains without an adequate treatment [32]. This lesion may lead to
pathological plasticity of the CNS that is associated with altered pain
sensations [33]. The main characteristics of BPA are the rapid onset of
pain (an effect which occurs immediately after the trauma) and the
long-lasting development of neuropathy, which may be evidenced
distant from the site of the lesion, either on the ipsilateral or
contralateral side [34,35].
A model of this neuropathic pain was originally described for rats
[35] and it was recently adapted to mice, where this avulsion induced
long-lasting mechanical and thermal hypernociception [36]. The
avulsion of brachial plexus in mice was not associated to autotomy,
a process that is frequently reported in several models of neuropathic
pain involving the transection of peripheral nerves. Also relevant in
this model is the fact that hypernociceptive responses observed
following the BPA persisted for a long period and that this effect could
be observed at distant sites from the injury, similarly to what happens
in the human.
4.2. Partial nerve lesions
Various partial nerve lesions have been developed experimentally
to study neuropathic pain. Such models include chronic constriction
injury of the sciatic nerve (CCI) [37]; partial sciatic nerve ligation (PSL)
[38] and spinal nerve ligation (SNL L5/L6, Chung model) [39,40],
which represent three of the best-characterized rodent models of
peripheral neuropathy (Fig. 1). These classic models produce similar
pain behaviours with some variation in the magnitude [41,42].
4.2.1. Sciatic nerve chronic constriction injury
Sciatic nerve CCI resembles human neuropathy resulting from
trauma of peripheral nerves, with some functional preservation of the
innervation (nerve entrapment or compression). The model of CCI is
one of the most commonly used models because it is reliable and
easily reproducible, and due to the presence of the constrictive
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tion and an epineurial inﬂammatory lesion [37,43,44]. This model in
mice is produced by three loose ligatures that are tied around the
common sciatic nerve exposed at the level of the mid-thigh, proximal
to the trifurcation of the nerve [45]. This procedure results in
intraneural oedema, which strangulates the nerve, effectively axoto-
mizing many but not all of the nerve axons [46-51]. It results in the
development of hyperalgesia to thermal stimulus, as indicated and
measured by reduced paw withdrawal latency to heat source.
Allodynia to mechanical stimuli also occurs. Moreover in some mice
strains autotomy was also observed after CCI, suggesting the
spontaneous pain presence.
4.2.2. Partial sciatic nerve injury (PNI)
In contrast with CCI model that consists in the ligation of the total
sciatic nerve, Seltzer et al. [38] developed in rat a partial sciatic nerve
injury that consists in the tight ligation of only 1/3 to 1/2 of the
common sciatic diameter. Malmberg and Basbaum [52] have reported
the same mouse model of partial nerve injury (PNI) that has been
largely employed to study mechanisms involved in neuropathic pain
and new therapeutic treatments [53-56].
Spared nerve injury (SNI) was more recently induced in mice in
accordance to procedure described by Decosterd and Woolf [57] in
rats, with minor modiﬁcations [58,59]. The three peripheral branches
(sural, common peroneal, and tibial nerves) of the sciatic nerve were
exposed without stretching the nerve structures. Both tibial and
common peroneal nerves were ligated and transected together. Some
authors developed a mouse model of partial sciatic nerve injury
following the ligation only of the common peroneal nerve [6,60] or
only of the tibial nerve [59] and have showed the mechanical
allodynia development, beginning 3 days after surgery and lasting 4
weeks. In the whole, mice subjected to PSI showed motor paralysis
immediately after surgery but recovered in a few days, so the PSI
models with less severe motor paralysis are likely to be more useful
than CCI.
4.2.3. Spinal nerve ligation (SNL)
Another experimental mononeuropathy model simulating human
causalgia was developed by Kim and Chung [39]: it consists of
ligating unilaterally and tightly spinal nerves L5 and/or L6 of rodents
at a location distal to the dorsal root ganglia and results in
behavioural signs that are similar to the symptoms of human
neuropathic pain, namely increased sensitivity to heat and painful
responses to otherwise non-painful mechanical stimuli [30]. Allody-
nia and hyperalgesia develop quickly after ligation and last for at
least 4 months. Although there are behavioural signs of spontaneous
pain (guarding, licking, and lifting of ipsilateral hind paw), autotomy
is absent in the spinal nerve ligation. Compared to CCI and PSI, the
spinal nerve ligation induces a more extensive and relevant damage
and has the advantage of having separate injured and intact spinal
segments. On the other hand, SNL requires the most extensive
surgical procedures of the three models. There have been only a
limited number of investigations of L5/L6 SNL, probably due to the
relatively difﬁcult surgical operation. However, Kiso et al. [61] have
recently developed an L5/L6 spinal nerve ligation model for
neuropathic pain also in mice that showed mechanical allodynia
beginning on day 1 and lasting for at least 2 months following
surgery. They have validated this model with a pharmacological
approach and with the analysis of the gene expression proﬁling in
dorsal root ganglia.
Ligation of L4 or L5 spinal nerve was also reported. Ligation of L4
spinal nerve is not a useful pain model, since it has an abundance of
motor ﬁbers and therefore causes severe motor deﬁcits that interfere
with behavioural tests [39]. The L5 ligation model has not been fully
characterized yet but induces long lasting hyperalgesia and mechan-
ical allodynia. Since single L5 nerve ligation is much easier to performthan L5/L6 ligation, this model provides a useful option especially in
studies involving mice [15,62-64].
4.2.4. Mouse model of neuropathic pain following photochemically
induced ischemia in the sciatic nerve
The ischemia was induced by unilateral irradiation of the sciatic
nerve with an argon ion laser after intravenous administration of
photosensitizing dye, erytrosin B. The partial nerve injury resulted in a
prolonged signiﬁcant decrease in withdrawal threshold of the
hindpaws to mechanical stimulation with von Frey hairs as well as
prolonged increased responsiveness to cold and heat stimulation. This
model is characterized by ischemic origin with minimal mechanical
trauma, unlike the models of partial nerve injury, which are primary
based on mechanical injury, thus the nerve injury produced is more
consistent and reproducible [65]. Moreover it is also important to note
that ischemia constitutes an important factor in human peripheral
nerve injury and neuropathy in conditions such as carpal tunnel
syndrome and diabetic neuropathy.
4.2.5. Polyethylene cuff
A recent murine model of neuropathic pain was developed by
Benbouzid et al. [66]. Neuropathy was induced by inserting a
polyethylene cuff around the main branch of the right sciatic nerve:
it induces a long-lasting mechanical allodynia (2 months) and
hyperalgesia to a hot thermal stimulus lasting 3 weeks [67].
4.2.6. Partial injury of the nerve supplying the tail
Back et al. [68] induced peripheral neuropathy in mice by a partial
injury of the nerve supplying the tail. The left superior caudal trunk
was exposed and transected at the level between the S3 and S4 spinal
nerves, and piece of the trunk, about 1 mm, was removed from the
proximal end. This surgery eliminated the S1–S3 spinal nerve
innervation of the tail via the superior caudal trunk. Partial injury of
the nerve supplying the tail produced a robust and consistent increase
of mechanical, cold and warm sensitivities (mechanical and thermal
allodynia) in the tail. Differently from other mouse models of partial
injury of the nerves supplying the hind paw, where the deformity of
the foot following the nerve injury makes it difﬁcult to conduct the
behavioural tests for neuropathic pain and impossible to perform
blind behavioural tests, this tail model can avoid these problems. The
application of both mechanical and thermal stimuli to the tail is
straightforward and in addition the lack of deformity in the tail after
the nerve injury easily allows blind behavioural tests. Surgical
procedures for this model are so simple that mice can be easily
used; in fact although some of the previous techniques developed for
rats can be applied to themouse, they are quite invasive approaches in
the smaller rodent.
4.2.7. Partial saphenous nerve injury in mouse
Recently a partial injury of the saphenous nerve (a purely sensory
nerve) was described in the rat, resulting in mechanical allodynia and
cold and heat hyperalgesia [69]. This lesion has several advantages
over sciatic injury, including improved animal welfare because no
motor damage occurs, ease of surgical access and thus a reduction in
surgical trauma, and that is highly amenable to pharmacological
intervention. Although the mouse saphenous nerve is ﬁne and friable,
this model was translated into the mouse and demonstrated that it
can be used for the study of primary afferent properties. It has
advantages over others for several reasons: it is surgically simple to
perform, produces clear, reproducible neuronal damage but also
leaves intact neurons available for electrophysiological study and
improves animal welfare owing to lack of motor nerve damage.
Interestingly while rats and mice show comparable behavioural
phenotypes after similar peripheral injuries in the many models
reported above, signiﬁcant differences were observed with the
saphenous lesion: mice did not develop hypersensitivity to thermal
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both heat hyperalgesia and cold allodynia. In contrast the changes in
mechanical responses with respect to both magnitude and duration
were similar in rats and mice [70].
4.2.8. Mouse model of trigeminal neuralgia
Orofacial pain disorders encompass a wide range of conditions
including trigeminal neuralgia, temporomandibular joint disorders,
periodontal pain, and atypical face pain. Trigeminal neuralgia is a form
of neuropathic pain characterized by severe lancinating pain in
orofacial regions innervated by the trigeminal nerve. Most cases of
trigeminal neuralgia are caused by sensory nerve root compression.
For the trigeminal neuralgia Vos et al. [71] developed a model in rat
due to the CCI of infraorbital trigeminal branch with loose ligatures.
Only one readily performed mouse model of trigeminal pain was
published. Xu et al. [72] have adapted the partial sciatic nerve ligation
model of Seltzer et al. [24] to the infraorbital branch of the trigeminal
nerve of mice. This model is a combination of the partial nerve ligation
(dental maxillary nerve ﬁbers and medial infraorbital nerve ﬁbers are
not injured) and spared nerve injury (trigeminal mandibular and
ophthalmic branches are intact) models of chronic pain. This partial
trigeminal injury in mice effectively mimics many of the qualities of
human trigeminal pain syndromes and induces a transient change of
grooming time and mechanical allodynia lasting for more than 3
weeks as well as many persistent anatomical changes.
5. Central and peripheral neuropathic pain models:
injection of TNF-alpha
Recently it has emerged that proinﬂammatory cytokines play an
important role in the onset and maintenance of neuropathic pain.
Tumour necrosis factor alpha (TNF), interleukin-1 and interleukin-6
are among the most involved cytokines [50,51,73]. Consistently intra-
or epineurial as well as intrathecal injection of TNF can elicit
neuropathic pain-like behaviours, suggesting that the prototypic
pro-inﬂammatory cytokine can act at several levels of the neuraxis to
modulate pain processing [74,75]. Gao et al. [62] and Narita et al. [76]
showed that also an application of TNF via lumbar puncture to mouse
spinal cord caused the development of mechanical allodynia and heat
hyperalgesia. These novel modalities of inducing painful symptoms
can be particularly useful to test innovative drug treatment targeting
the immune/proinﬂammatory component of neuropathic pain.
6. Murine models of the disease-induced neuropathic pain
In order to havemodels that more directlymimic prevalent clinical
pain syndromes, researchers have attempted to induce the disease
that will thereafter cause the neuropathic damage. These diseases
include painful peripheral diabetic neuropathy, post-herpetic neural-
gia, cancer-associated neuropathic pain, multiple sclerosis neuro-
pathic pain, complex regional pain syndrome type I, HIV (and anti-
retroviral)-induced painful neuropathy.
6.1. Multiple sclerosis
Central neuropathic pain is a common but little understood
symptom associated with the autoimmune disease multiple sclerosis
(MS). The experimental autoimmune encephalomyelitis (EAE) and
Theiler's murine encephalomyelitis virus (TMEV) models in mice
represent the two most common animal models of MS and their use
has led to a greater understanding of MS and the development of
clinical therapies. EAE is normally induced in mice by immunization
with myelin oligodendrocyte glycoprotein and shares many features
of the pathology seen in MS patients, including widespread CNS
inﬂammation, demyelination and locomotion impairments. Mice
with this form of EAE develop a robust tactile allodynia early in thedisease process prior to any overt neurological deﬁcits [77,78]
similar to some patients with MS [79-81]. The viral model of MS is
represented by mice infected with TMEV. Intracerebral inoculation
of mice with TMEV induces a biphasic CNS disease characterized by
inﬂammatory inﬁltration, demyelination, remyelination, and axonal
damage that correlate with neurological disability. In these animals
mechanical allodynia and thermal hyperalgesia are always observed
[82].
6.2. Posherpetic peripheral neuropathic pain model
Postherpetic neuralgia is a persistent chronic burning pain often
associated with allodynia and/or hypoesthesia that may occur as a
sequela of reactivation of latent herpes-zoster virus in dorsal root
ganglia. While the disease is invariably painful in its acute phase during
the skin rash, the incidence of postherpetic neuralgia over months or
years after the disease depends on several risk factors, including the age
of patient, the intensity of shingle eruption as well as the area of the
affected skin [83]. It is clear now thatmany of the DRG neurons affected
by the virus degenerate, most probably by themechanism of apoptosis,
as has been discussed for virtually all virus diseases involving the
nervous system [84]. Due to the species speciﬁcity of varicella zoster
virus, the identiﬁcation of rodent models has been particularly difﬁcult.
A ratmodel of varicella zoster virus-associated pain has been developed
some years ago by Fleetwood-Walker et al. [85] and recently reﬁned
[5]. While no mouse model of varicella zoster virus-induced pain has
ever been described, a few papers report that the inoculation of mice
with herpes simplex virus type-1 (HSV-1) causes herpes zoster-like
skin lesions and pain-related responses (tactile allodynia and mechan-
ical hyperalgesia) from 5 days after the inoculation up to 40 days
[86,87]. However due to the fact that HSV-1 is not the relevant virus in
the human, they cannot be considered appropriate models for clinical
post-herpetic neuropathic pain.
6.3. HIV-associated sensory neuropathy
Human immunodeﬁcient virus (HIV)-associated sensory neurop-
athy (HIV-SN) is the most common neurological complication of HIV
infections, symptomatically affecting over one third of patients with
HIV. The symptoms of HIV-sensory neuropathy are dominated by
neuropathic pain, which is often excruciating. The pain is usually
most severe on the soles of the feet, making walking difﬁcult. There
are presently no effective therapies for HIV-sensory neuropathy, and
moreover until recently there has been no robust animal model of
HIV-SN in which candidate therapeutic agents could be tested. In the
last years two different models of HIV-SN have been published in the
mouse and in the rat. A recent study of Keswani et al. [88] developed
such a model consisting in transgenic mice expressing the HIV coat
protein gp120 under a GFAP promoter, characterized by distal
sensory axonal degeneration as seen in HIV patients with early
stages of HIV-SN.
A reliable model of HIV neuropathy has been described, only in rat,
by the group of Wallace and Rice, based on the contact between the
HIV envelope protein gp120 and the rodent sciatic nerve [89,90]. The
study of HIV-induced neuropathy is even more difﬁcult since a toxic
neuropathy is precipitated also by the use of nucleoside reverse
transcriptase inhibitors normally part of antiretroviral therapy.
Hopefully these models should be helpful for the study of both HIV
and antiretroviral precipitated neuropathy.
6.4. Diabetic peripheral neuropathic pain model
Distal symmetric sensory neuropathy is a common complication of
diabetes. Diabetic patients can suffer from either a painless syndrome,
with loss of sensations to touch, pain or temperature, or a painful
disorder characterized by spontaneous pain, mechanical hyperalgesia
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Experimental models of the disease exhibit responses similar to those
present in patients [91-93], including spontaneous pain [94], decrease
in mechanical nociceptive thresholds [95] and/or hypoalgesia
characterized by decreased responses to mechanical and thermal
stimuli. In particular short-term diabetes has been shown to be
associated with thermal and mechanical hyperalgesia, whereas long-
term diabetes is associated with thermal and mechanical hypoalgesia
[96,97]. A few murine diabetic models are available either genetically
determined or drug-induced. NOD (non-obese diabetic) mice [98,99]
develop spontaneous diabetes. Spontaneous autoimmune diabetes in
NOD mice involves a long-term inﬂammatory process that closely
resembles the human type 1 diabetes [100]. NOD mice develop
inﬂammation of pancreatic islets at 3 weeks of age, but do not begin to
develop diabetes until 10 weeks later, while they develop a signiﬁcant
time-dependent hyperalgesia, which does not correlate with the
increase in the plasma glucose concentration but appears very early
and is signiﬁcant at young age (8–10 weeks), so preceding the
hyperglycaemic state of mice. Similarly, also in human it is known that
diabetic complications, including hyperalgesia, start to develop during
the early inﬂammatory stage of the disease, even before establishing
the hyperglycemia and/or the glicosuria necessary for diabetes
diagnosis [101]. Insulin resistant ob/ob and db/db mice [102-104]
develop obesity and type 2 diabetes as a result of spontaneous genetic
mutations that cause a decrease in functional leptin (ob/ob) or its
receptor (db/db). In the 11-week-old leptin-deﬁcient ob/ob mice,
[105,106] deﬁcits in motor nerve and hind limb digital sensory nerve
conduction velocity are present together with a remarkable loss of
intraepidermal nerve ﬁbers and tactile allodynia. Recently other
mouse model is explored for its contribution to diabetes research:
C57BL/6J mouse that develops obesity and type 2 diabetes when fed a
high fat diet [107]. The presence of altered thermal pain sensitivity has
been reported also in a complex double transgenic mouse model of
type 1 diabetes (TCR-SFE/Ins-HAmouse) [108] that becomes hyper-
glycaemic spontaneously by 4–6 weeks of age [109]. This model
parallels human diabetes in that it is immune-mediated, affects both
genders equally and results from selective destruction of islet beta
cells. However the most commonly used model for the study of this
pain remains that of streptozotocin (STZ) or alloxan-induced diabetic
neuropathy. STZ and alloxan kill insulin-secreting islet Langerhans
pancreatic cells and produces the rapid development of hyperglycae-
mia [110]. In mice, single or repeated i.p. injection of STZ induces long
lasting thermal and mechanical hyperalgesia and cold, thermal and
mechanical allodynia [55,111]. In contrast to the STZ rat model, mice
rendered diabetic with STZ and studied over sufﬁcient periods of time
(e.g., 4–8 months), do exhibit more robust features of neurodegen-
eration [112]. Interestingly insulin treatment abolishes pain and
hyperalgesia [113]. We must underline that there are many features
and underlying mechanisms that differ from human disease: this
model produces severe distress to the animal with deterioration of
general conditions and it was difﬁcult to interpret data or obtain clear
pain scores; moreover STZ has toxic effects on cells other than islet
beta cells that might confound results making it important to use
other models of diabetes.
7. Cancer-related neuropathic pain
Cancer-induced neuropathic pain may result from compression of
nerve, plexus, or roots, or direct inﬁltration by the growing tumour, or
secondarily from changes in the neuronalmilieu resulting from cancer
growth or from the resulting inﬂammatory response such as tissue pH
(acidosis), release of tumour algogens or circulating chemokines and
cytokines [114]. Moreover it is increasingly recognized that cancer-
related neuropathic pain can also arise as a consequence of cancer-
directed therapy, such as surgery, radiotherapy and chemotherapy
[115].7.1. Models of cancer-related neuropathic pain
Several murine models of direct inoculation of compatible
murine cancer cells have been developed, such as squamous cell
carcinoma into the hind paw and hepatocellular carcinoma cells into
thigh muscle [116], which result in spontaneous pain behaviour,
heat hyperalgesia and mechanical allodynia over varying time
courses. Early onset pain behaviour was noted 1–3 days after
inoculation of squamous cell carcinoma cells into the mouse hind
paw. There was no sign of tumour inﬁltration into the nerve, although
plantar nerves were clearly encapsulated by tumour cells, producing
substantial compression of nerves and a degree of nerve damage.
However over 60% of mice died within 16 days post-surgery due to
lung metastasis [117]. A different modality is the direct inoculation of
tumour cells close to the nerve. Meth-A sarcoma cells injected around
mouse sciatic nerve resulted in the growth of a tumour mass
surrounding the nerve with a maximum pain behaviours by day 21
post-inoculation, when histological signs of nerve damage were
identiﬁed [118].
8. Chemotherapy-induced peripheral neuropathy
Peripheral neuropathy is a very frequent and severe side effect of
chemotherapy and is often the limiting factor for achieving effective
doses. Neurotoxicity is particular problematic for vinka alkaloids,
platinum compounds, and taxols. Chemotherapy-induced neuropathy
may continue after the cessation of therapy. When administered to
mice, these chemicals also produce neuropathy which may be used to
study causes, prevention and treatment of their neurotoxicity. Several
studies have attempted to model chemotherapy induced peripheral
neuropathy. Recently three mice models have been reported.
8.1. Vincristine-induced peripheral neuropathy model
Vincristine, a vinka alkaloid, prevents tumour cell replication via
inhibition of tubulin polymerisation and is currently in wide clinical
use as a treatment for leukaemia and lymphoma. However it shows
the serious adverse effect of neuropathic pain, which limits its clinical
use. Experimental models of vincristine-induced peripheral neuro-
pathic pain have been established also in mice. Repeated injections of
the chemotherapic agent produced dose-dependent mechanical
allodynia in two strains of mice (ICR and BALB/c), which was
observed even after cessation of vincristine administration [119,120].
8.2. Paclitaxel (taxol)-induced peripheral neuropathy model
Paclitaxel is an antineoplastic agent derived from the Paciﬁc yew
tree Taxus brevifolia and is used to treat a variety of cancers, including
ovarian and breast tumours and non-small cell lung cancer. Taxol
binds to tubulin, at a site different from that used by the vinka
alkaloids and blocks deassembly of microtubules, followed by an
arrest of mitosis. Its effectiveness is limited by the development of
severe painful peripheral neuropathy that is dose-dependent.
A number of mouse models of taxol-induced neuropathic pain
have been reported. Both allodynia and thermal hyperalgesia can be
detected in taxol-treated mice. Hidaka et al. [121] demonstrated that
paclitaxel intraperitoneal administration at a single dose of 10 mg/kg
or more in mice induces painful peripheral neuropathy, which is
similar to the muscle pain in humans after this chemotherapeutic
treatment. Painful peripheral neuropathy began after 24 h and lasted
for 72 h: these ﬁndings suggest a recovery in functions of impaired
sensory neurons. So, this animal model presented transient neuro-
pathic pain with quick onset and the mice recovered within a few
days. Furthermore, these time courses were similar to those of human
muscle pain after administration of paclitaxel at a dose of 180 mg/m2
in cancer patients [122,123].
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intraperitoneal treatment of mice (4 mg/kg) led to a decrease in
both thermal and mechanical nociceptive threshold as well as A-ﬁber
speciﬁc hypersensitization. Paclitaxel-treated cancer patients support
these results, since they also show Aβ ﬁber hypersensitivity [125].
Several other mice models presenting paclitaxel-induced neurop-
athy have been reported, but in these models only repeated
administration of high dose paclitaxel induced pathological changes
such as axonal degeneration and neuropathy lasting for a long time,
sometimes with no recovery [126,127]. In these studies the paclitaxel
administration in mice has been performed multiple times on
consecutive /alternative days or in a single but very high dose.
8.3. Cisplatin-induced peripheral neuropathy
Cisplatin is used to treat several cancers; it induces polyneuro-
pathy that is dose- and treatment duration-dependent and can last for
over 10 years. Repeated daily i.p. injections of cisplatin produce in
mice mechanical allodynia and hyperalgesia. So these models have
been used to test a number of experimental treatments that may be
useful to alleviate cisplatin neuropathy [128]. The pronounced
neurotoxicity of this drug is supposed to be due to cisplatin-induced
DNA adduct made of intrastrand cross-links. Interestingly, Dzagnidze
et al. [129] demonstrated an accelerated accumulation of unrepaired
intrastrand cross-links in DRG neuronal cells of mice with dysfunc-
tional nucleotide excision repair. In such animals this phenomenon
coincided with an earlier onset of peripheral polineuropathy-like
functional disturbance of their sensory nervous system. This new
model accentuates the crucial role of effectual DNA repair capacity
in the target cells for the individual risk of therapy-induced
polineuropathy.
9. Inherited-induced neuropathies
The normal function of peripheral nerves requires myelination of
axons by Schwann cells. These highly specialized glial cells form
myelin sheaths that facilitate the rapid impulse propagation along the
axon. In recent years, numerous membrane proteins that are localized
to myelin and axon-glia junctions have been molecularly cloned and
functionally characterized [130,131]. Many of these proteins could
also be associated with inherited myelin diseases and neuropathies in
humans. Recent progress in human genetics and neurobiology has led
to the identiﬁcation of variousmutations in particular myelin genes as
the cause for many of the known inherited demyelinating peripheral
neuropathies. Hereditary motor and sensory neuropathies, deﬁned by
single gene mutations, constitute a heterogeneous group of diseases,
referred to as Charcot-Marie-Tooth (CMT) disease by geneticists.
Mutations in three distinct myelin genes PMP22, P0, and connexin 32
cause the three major demyelinating subtypes of Charcot-Marie-
Tooth disease, CMT1A, CMT1B and CMTX, respectively. With the
identiﬁcation of these responsible disease genes signiﬁcant progress
has been made in understanding CMT disease mechanisms. The main
clinical feature of all forms of CMT is the symmetric and distally
pronouncedmuscle weakness of the lower limb, and to a lesser extent
of the upper limb, which slowly progresses proximally. Initially, the
muscle atrophy affects the distal leg and intrinsic foot muscles,
causing steppage gait and foot deformities. Sensory deﬁcits are a
common feature but less prominent [132]. Although positive sensory
symptoms are classically considered a hallmark of acquired neurop-
athies, sensory nerve involvement in CMT is well demonstrated on
neurophysiological and pathological grounds and some observations
suggest that clinical sensory manifestations are common in CMT.
There are some papers which evaluate the presence of neuropathic
pain in CMT patients. Carter et al. [133] report a clinical study
according to which neuropathic pain is a signiﬁcant problem for many
people with CMT, using a validated measurement tool, the neuro-pathic pain scale, and concluded that symptoms reported by CMT
patients are similar to those reported by patients with neuropathic
pain. According to these authors, the frequency and intensity of pain
reported in CMT is comparable in many ways to post-herpetic
neuralgia, diabetic neuropathy and peripheral nerve injury. Since pain
is susceptible to treatment, it warrants evaluation in CMT patients and
it should be considered as a relevant symptom. Also Gemignani et al.
[134] reported positive sensory symptoms in 58% of CMT patients,
including neuropathic pain. Recently, Houlden et al. [135] reported
the results of a study on the hereditary sensory and autonomic
neuropathy type I (HSAN I), that is the most frequent type of
hereditary neuropathy that primarily affects sensory neurons. These
authors showed that patients presented positive symptoms such as
limb pain, positive sensory symptoms of shooting and burning, and
paraesthesia. Also, Padua et al. [136] following to a multicenter
multidimensional study underlined that pain should be considered as
a relevant symptom in CMT patients.
9.1. Mouse models of inherited neuropaties
There are a few mouse models of inherited neuropathy. A
particular advantage of inherited neuropathy animal models is that
the onset and progress of the disease can be much better
characterised than in human patients, who are usually investigated
only when symptoms have already developed [137]. However these
models are not fully useful for the detection of the presence of pain,
since the severe compromission of motor ﬁbers due to the pathology
does not allow the evaluation of the classical neuropathic pain
symptoms, such as allodynia and hyperalgesia. In these models it
should be particularly important the application of integrated
procedures for the evaluation of pain-associated behaviour.
9.1.1. Spontaneous inherited neuropathy
When PMP22 was identiﬁed as a myelin gene [138] a search for
possible spontaneous mutations in mice was performed. Two well-
known mutants affected by Schwann cell-mediated neuropathies
[139], the Trembler (Tr) and Trembler-J (Tr-J) mouse, have been
found to carry particular mutations in the PMP22 gene [140,141]. The
Tr mouse is associated with more severe pathological alterations as
compared with the Tr-J mutant. The spontaneous mouse mutants Tr
and Tr-J both carry point mutations in the PMP22 gene [140,141] and
share pathological features with CMT1A [142]. Indeed, the same
mutation has been identiﬁed in mouse and in one human CMT1A
family [143]. However, the subcellular consequences of PMP22
misfolding in Tr mice and PMP22 overexpression in the majority of
CMT1A cases are different [144].
9.1.2. Engineered inherited neuropathies
Overexpression of wild-type PMP22 can only be modeled by
transgenic extracopies of the wild-type gene. PMP22 transgenic mice,
with PMP22 overexpression, exhibit clinical abnormalities, such as
severe dysmyelinated phenotype, reduced nerve conduction velocity
and lower grip strength, that mimic ﬁndings in CMT1A patients and
demonstrates the variability of disease expression as a function of
increased gene dosage [145-150]. An interesting “inducible”model of
CMT1A has also been generated in which PMP22 overexpression was
achieved under cell-type-speciﬁc control of a tetracyclin-activable
transactivator [151]. PMP22-deﬁcient knock-out mice have been also
generated by homologous recombination [152,153]: peripheral
nerves of homozygous null mutants were severely affected, in that
they showed focal hypermyelination; heterozygous mice have a
phenotype much milder than the homozygous mice, demonstrating
that PMP22 is a dosage-sensitive myelin component.
Also mutations encoding for the myelin components P0 and
connexin 32 are clinically relevant, since they were found in the
majority of patients with inherited demyelinating neuropathies [154].
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completely deﬁcient in gap-junction protein connexin 32 (32-/-)
mimic demyelinating forms of inherited neuropathies, such as CMT
neuropathies type 1B and CMT type 1X, respectively. Mutations in the
human Cx32 gene have been linked to the X-linked form of CMT
(CMTX) [155]. Mice deﬁcient in the gene for Cx32 show pathological
alterations in peripheral nerves comparable to those seen in the CMTX
patients [137].
10. Conclusion
Important advances have been achieved in the study of neuro-
pathic painwith the use of themany animalmodels that are becoming
increasingly available in the mouse. Whereas the most used models
still remain those based on nerve ligation, of great importance is the
fact that in the last years other techniques are being developed that
mimic more closely clinical pain syndromes, often by attempting to
induce the disease or the genetic mutation associated to neuropathic
pain. Moreover it is now clear that other important variables such as
sex, age and strain should be more carefully taken into consideration
when performing the experimental studies. However, by widening
the number of animal model of neuropathic pain, new challenges
have emerged. Although neuropathic pain with various aetiologies
appears to lead to similar behavioural end points, it is becoming clear
that they could respond differentially to pharmacological agents,
suggesting that distinct mechanisms may underlie speciﬁc neuro-
pathic states deriving from different pathological conditions. Partic-
ularly interesting is the observation that in most, if not all, the
experimental models reported, a relevant role in the development
and maintenance of neuropathic pain is played not only by sensitive
andmotor neurons, but also by immunocompetent cells both resident
in the peripheral and central nervous system, such as Schwann cells
and microglia, and recruited from blood. A comparative study of the
molecular pathways at various levels in different neuropathies will
facilitate our knowledge of this condition, and the identiﬁcation of
common, either neuronal or not, markers in neuropathic pain should
be amain objective for pain scientists in the next years. Hopefully, this
will help to ﬁnally translate basic science knowledge into the
development of new clinically effective treatments.
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